vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v19i6.2151vsp-2508Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWЗуд при атопическом дерматите: от этиологических особенностей к терапевтической тактикеPruritus and Atopic Dermatitis: from Etiological Features to Managementhttps://orcid.org/0000-0003-2252-8570МурашкинН. Н.MurashkinNikolay N.

Мурашкин Николай Николаевич, доктор медицинских наук, заведующий отделением дерматологии с группой лазерной хирургии, заведующий лабораторией патологии кожи у детей отдела научных исследований в педиатрии НМИЦ здоровья детей, профессор кафедры дерматовенерологии и косметологии ЦГМА, профессор кафедры педиатрии и детской ревматологии Первого МГМУ им. И.М. Сеченова, заведующий отделом детской дерматологии НИИ педиатрии и охраны здоровья детей ЦКБ РАН

119296, Москва, Ломоносовский пр-т, д. 2, стр. 1

m_nn2001@mail.ruhttps://orcid.org/0000-0002-0858-8780ОпрятинЛ. А.OpryatinLeonid A.https://orcid.org/0000-0002-4107-4642ЕпишевР. В.EpishevRoman V.https://orcid.org/0000-0002-6034-8231МатерикинА. И.MaterikinAlexander I.https://orcid.org/0000-0002-8232-8936АмбарчянЭ. Т.AmbarchianEduard T.https://orcid.org/0000-0002-0081-0981ИвановР. А.IvanovRoman A.https://orcid.org/0000-0001-9777-0156ФедоровД. В.FedorovDmitriy V.https://orcid.org/0000-0002-8268-069XКуколеваД. С.KukolevaDaria S.Национальный медицинский исследовательский центр здоровья детей; Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет); Центральная государственная медицинская академия Управления делами Президента РФ; НИИ педиатрии и охраны здоровья детей ЦКБ РАНРоссияNational Medical Research Center of Children’s Health; Sechenov First Moscow State Medical University (Sechenov University); Central State Medical Academy of Department of Presidential Affairs; Research Institute of Pediatrics and Children’s Health in “Central Clinical Hospital of the Russian Academy of Sciences”Russian FederationНациональный медицинский исследовательский центр здоровья детейРоссияNational Medical Research Center of Children’s HealthRussian Federation202025122020196468476Copyright © Мурашкин Н.Н., Опрятин Л.А., Епишев Р.В., Материкин А.И., Амбарчян Э.Т., Иванов Р.А., Федоров Д.В., Куколева Д.С., 20202020Мурашкин Н.Н., Опрятин Л.А., Епишев Р.В., Материкин А.И., Амбарчян Э.Т., Иванов Р.А., Федоров Д.В., Куколева Д.С.Murashkin N.N., Opryatin L.A., Epishev R.V., Materikin A.I., Ambarchian E.T., Ivanov R.A., Fedorov D.V., Kukoleva D.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/2508

Одним из основных клинических проявлений атопического дерматита является зуд, значительно ухудшающий качество жизни пациентов в детском возрасте. Научные представления о его патофизиологической основе в настоящее время претерпели серьезные изменения. В том числе опровергнута исключительная роль гистамина в развитии зуда, а также приведены сведения об участии иммунной системы в его поддержании. В статье представлены современные данные о дифференциальных подходах к терапии зуда в зависимости от его этиопатогенетических характеристик. Уделено внимание значимости дерматокосметики в восстановлении кожного барьера как первой ступени в профилактике зуда при атопическом дерматите. Представлены результаты клинических исследований, свидетельствующие об эффективности применения топических средств на основе инновационного компонента с противозудным действием STIMU-TEX.

Pruritus is one of the main clinical manifestations of atopic dermatitis, and it significantly reduces the quality of life of patients in childhood. Scientific images on its pathophysiological basis have now undergone significant changes. The histamine exceptional role in pruritus development was confounded, as well as data on immune system involvement in its maintenance was given. This article presents current data on differential approaches to pruritus management depending on its etiopathogenetic characteristics. The role of dermocosmetics in restoration of the skin barrier as the first stage prevention of pruritus in atopic dermatitis was considered. The results of clinical studies showing efficacy of topical agents (innovative component with anti-pruritic action — STIMU-TEX) application are presented.

зудатопический дерматиткожный барьердерматокосметикаэмоленты-плюсpruritusatopic dermatitisskin barrierdermocosmeticsemollient plusСтатья опубликована при поддержке компании «Аванта»The article has been supported by “Avanta”ReferencesMollanazar NK, Koch SD, Yosipovitch G. Epidemiology of Chronic Pruritus: Where Have We Been and Where Are We Going? Curr Derm Rep. 2015;4:20–29. doi: 10.1007/s13671-014-0093-y.Mollanazar NK, Koch SD, Yosipovitch G. Epidemiology of Chronic Pruritus: Where Have We Been and Where Are We Going? Curr Derm Rep. 2015;4:20–29. doi: 10.1007/s13671-014-0093-y.Blome C, Radtke MA, Eissing L, Augustin M. Quality of Life in Patients with Atopic Dermatitis: Disease Burden, Measurement, and Treatment Benefit. Am J Clin Dermatol, 2016;17(2):163–169. doi: 10.1007/s40257-015-0171-3.Blome C, Radtke MA, Eissing L, Augustin M. Quality of Life in Patients with Atopic Dermatitis: Disease Burden, Measurement, and Treatment Benefit. Am J Clin Dermatol, 2016;17(2):163–169. doi: 10.1007/s40257-015-0171-3.Круглова Л.С., Генслер Е.М. Атопический дерматит: новые горизонты терапии // Медицинский Алфавит. Дерматология. — 2019. — Т. 1. — № 7(382). — С. 29–32. doi: 10.33667/2078-5631-2019-1-7(382)-29-32.Kruglova LS, Gensler EM. Atopic dermatitis: new horizons of therapy. Medical Alphabet. Dermatology. 2019;1(7):29–32. (In Russ). doi: 10.33667/2078-5631-2019-1-7(382)-29-32.Andrew D, Craig AD. Spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch. Nat Neurosci. 2001;4(1):9–10. doi: 10.1038/82924.Andrew D, Craig AD. Spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch. Nat Neurosci. 2001;4(1):9–10. doi: 10.1038/82924.Chuquilin M, Alghalith Y, Fernandez KH. Neurocutaneous disease. J Am Acad Dermatol. 2016;74(2):197–212. doi: 10.1016/j.jaad.2015.04.060.Chuquilin M, Alghalith Y, Fernandez KH. Neurocutaneous disease. J Am Acad Dermatol. 2016;74(2):197–212. doi: 10.1016/j.jaad.2015.04.060.Адаскевич В.П. Кожный зуд. Дерматологический и междисциплинарный феномен. М.: БИНОМ; 2014. 260 с.Adaskevich VP. Kozhnyi zud. Dermatologicheskii i mezhdistsiplinarnyi fenomen. Moscow: BINOM; 2014. 260 p.B ieber T, Leung DYM. Atopic Dermatitis. CRC Press; 2002. p. 49.Bieber T, Leung DYM. Atopic Dermatitis. CRC Press; 2002. p. 49.Verze L, Carla V-P, Maurizo S, et al. Distribution of GAP-43 nerve fibers in the skin of the adult human hand. The Anatomical Record Part A: Discoveries in Molecular, Cellular, and Evolutionary Biology. Anat Rec A Discov Mol Cell Evol Biol. 2003;272A(1):467–473. doi: 10.1002/ar.a.10056.Verze L, Carla V-P, Maurizo S, et al. Distribution of GAP-43 nerve fibers in the skin of the adult human hand. The Anatomical Record Part A: Discoveries in Molecular, Cellular, and Evolutionary Biology. Anat Rec A Discov Mol Cell Evol Biol. 2003;272A(1):467–473. doi: 10.1002/ar.a.10056.Abbracchio MP, Reggiani AM. Pain and nociception. In: Galizia CG, Lledo P-M, eds. Neurosciencesefrom molecule to behavior: a university textbook. 2nd ed. Berlin, Germany: Springer Berlin Heidelberg; 2013. pp. 455–459.Abbracchio MP, Reggiani AM. Pain and nociception. In: Galizia CG, Lledo P-M, eds. Neurosciencesefrom molecule to behavior: a university textbook. 2nd ed. Berlin, Germany: Springer Berlin Heidelberg; 2013. pp. 455–459.Roosterman D, Goerge T, Schneider SW, et al. Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol Rev. 2006;86(4):1309–1379. doi: 10.1152/physrev.00026.2005.Roosterman D, Goerge T, Schneider SW, et al. Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol Rev. 2006;86(4):1309–1379. doi: 10.1152/physrev.00026.2005.Lawson SN. Phenotype and function of somatic primary afferent nociceptive neurones with C-, Adelta- or Alpha/beta-fibres. Exp Physiol. 2002;87(2):239–244.Lawson SN. Phenotype and function of somatic primary afferent nociceptive neurones with C-, Adelta- or Alpha/beta-fibres. Exp Physiol. 2002;87(2):239–244.Elder D. Histology of the skin. In: Elder D, ed. Lever’s histopathology of the skin. 9th ed. Philadelphia (PA): Lippincott Williams and Wilkins; 2005.Elder D. Histology of the skin. In: Elder D, ed. Lever’s histopathology of the skin. 9th ed. Philadelphia (PA): Lippincott Williams and Wilkins; 2005.Myers MI, Peltier AC, Li J. Evaluating dermal myelinated nerve fibers in skin biopsy. Muscle Nerve. 2013;47(1):1–11. doi: 10.1002/mus.23510Myers MI, Peltier AC, Li J. Evaluating dermal myelinated nerve fibers in skin biopsy. Muscle Nerve. 2013;47(1):1–11. doi: 10.1002/mus.23510Thestrup-Pedersen К. Clinical aspects of atopic dermatitis. Clin Ехр Dernatol. 2000;25(7):535–543. doi: 10.1046/j.1365-2230.2000.00696.x.Thestrup-Pedersen К. Clinical aspects of atopic dermatitis. Clin Ехр Dernatol. 2000;25(7):535–543. doi: 10.1046/j.1365-2230.2000.00696.x.Krause L, Shuster S. Mechanisms of action of antipruritic drugs. Br Med J (Clin Res Ed). 1983;287(6400):1199–1200. doi: 10.1136/bmj.287.6400.1199.Krause L, Shuster S. Mechanisms of action of antipruritic drugs. Br Med J (Clin Res Ed). 1983;287(6400):1199–1200. doi: 10.1136/bmj.287.6400.1199.Greaves МW. Antihistamines. Dermatol Clin. 2001;19(1): 53–62. doi: 10.1016/s0733-8635(05)70229-1.Greaves МW. Antihistamines. Dermatol Clin. 2001;19(1): 53–62. doi: 10.1016/s0733-8635(05)70229-1.Rukwied R, Неуеr C. Cutaneous reactions and sensations after intracutaneous injection of vasoactive intestinal polypeptide and acetylholine in atopic eczema patients and healthy controls. Аrсh Dermatol Res. 1998;290(4):198–204. doi: 10.1007/s004030050290.Rukwied R, Неуеr C. Cutaneous reactions and sensations after intracutaneous injection of vasoactive intestinal polypeptide and acetylholine in atopic eczema patients and healthy controls. Аrсh Dermatol Res. 1998;290(4):198–204. doi: 10.1007/s004030050290.Vogelsang М, Heyer С, Hornstein ОР. Acetylcholine induces different cutaneous sensations in atopic and non-atopic subjects. Acta Derm Venereol. 1995;75(6):434–436. doi: 10.2340/0001555575434436.Vogelsang М, Heyer С, Hornstein ОР. Acetylcholine induces different cutaneous sensations in atopic and non-atopic subjects. Acta Derm Venereol. 1995;75(6):434–436. doi: 10.2340/0001555575434436.Heyer С, Vogelsang М, Hornstein ОР. Acetylholine is аn inducer of itching in patients with atopic eczema. J Dermatol. 1997;24(10): 621–625. doi: 10.1111/j.1346-8138.1997.tb02305.x.Heyer С, Vogelsang М, Hornstein ОР. Acetylholine is аn inducer of itching in patients with atopic eczema. J Dermatol. 1997;24(10): 621–625. doi: 10.1111/j.1346-8138.1997.tb02305.x.Ikoma А, Fartasch М, Неуеr Р, et al. Painful stimuli evoke itch in patients with chronic pruritus: central sensitization for itch. Neurology. 2004;62(2):212–217. doi: 10.1212/wnl.62.2.212.Ikoma А, Fartasch М, Неуеr Р, et al. Painful stimuli evoke itch in patients with chronic pruritus: central sensitization for itch. Neurology. 2004;62(2):212–217. doi: 10.1212/wnl.62.2.212.Steinhoff М, Vergnolle N, Young SH, et аl. Agonists of proteinase activated receptor 2 induce inflammation bу а nеurogenic mechanism. Nat Med. 2000;6(2):151–158. doi: 10.1038/72247.Steinhoff М, Vergnolle N, Young SH, et аl. Agonists of proteinase activated receptor 2 induce inflammation bу а nеurogenic mechanism. Nat Med. 2000;6(2):151–158. doi: 10.1038/72247.Di Marzo V, Blumberg РМ, Szallasi А. Endovanilloid signalling in pain. Curr Opin Neurobiol. 2002;12(4):372–379. doi: 10.1016/s0959-4388(02)00340-9.Di Marzo V, Blumberg РМ, Szallasi А. Endovanilloid signalling in pain. Curr Opin Neurobiol. 2002;12(4):372–379. doi: 10.1016/s0959-4388(02)00340-9.Caterina МJ, Julius D. Тhе vanilloid receptor а mоlесulаr gateway to the pain pathway. Аnn Rev Neurosci. 2001;24:487–517. doi: 10.1146/annurev.neuro.24.1.487.Caterina МJ, Julius D. Тhе vanilloid receptor а mоlесulаr gateway to the pain pathway. Аnn Rev Neurosci. 2001;24:487–517. doi: 10.1146/annurev.neuro.24.1.487.Stander S, Luger Т, Metze D. Treatment of prurigo nodularis with topical capsaicin. J Аm Acad Dermato. 2001;44(3):471–478. doi: 10.1067/mjd.2001.110059.Stander S, Luger Т, Metze D. Treatment of prurigo nodularis with topical capsaicin. J Аm Acad Dermato. 2001;44(3):471–478. doi: 10.1067/mjd.2001.110059.Stander S, Luger ТА. Antipruritic effects of pimecrolimus and tacroli mus. Haurtarzt. 2003;54(5):413–414. doi: 10.1007/s00105-003-0521-6.Stander S, Luger ТА. Antipruritic effects of pimecrolimus and tacroli mus. Haurtarzt. 2003;54(5):413–414. doi: 10.1007/s00105-003-0521-6.Dvorak М, Watkinson А. McClone Р, Rulwied R. Histamine induced responses аrе attenuated by а cannabinoid receptor agonist in human skin. Inflamm Res. 2003;52(6):238–245. doi: 10.1007/s00011-003-1162-z.Dvorak М, Watkinson А. McClone Р, Rulwied R. Histamine induced responses аrе attenuated by а cannabinoid receptor agonist in human skin. Inflamm Res. 2003;52(6):238–245. doi: 10.1007/s00011-003-1162-z.Kеmеnу L. Comparative study of S235 сrеаm and hydrocortisone 1% in patients with atopic dermatitis. J Аm Acad Dermatol. 2006;52(3 Supрl):P68. doi: 10.1016/j.jaad.2004.10.282.Kеmеnу L. Comparative study of S235 сrеаm and hydrocortisone 1% in patients with atopic dermatitis. J Аm Acad Dermatol. 2006;52(3 Supрl):P68. doi: 10.1016/j.jaad.2004.10.282.Nilsson HJ, Levinsson A, Schouenborg J. Cutaneous field stimulation (CFS): a new powerful method to combat itch. Pain. 1997; 71(1):49–55. doi: 10.1016/s0304-3959(97)03339-3.Nilsson HJ, Levinsson A, Schouenborg J. Cutaneous field stimulation (CFS): a new powerful method to combat itch. Pain. 1997; 71(1):49–55. doi: 10.1016/s0304-3959(97)03339-3.Fjellner В, Hagermark O. The influence of the opiate antagonist naloxone on experimental pruritus. Acta Derm Venereol. 1984; 64(1):73–75.Fjellner В, Hagermark O. The influence of the opiate antagonist naloxone on experimental pruritus. Acta Derm Venereol. 1984; 64(1):73–75.Kо МG, Naughton NN. An experimental itch model in monkeys: characterization of intrathecal morphine-induced scratching and antinociception. Anesthesiology. 2000;92(3):795–805. doi: 10.1097/00000542-200003000-00023.Kо МG, Naughton NN. An experimental itch model in monkeys: characterization of intrathecal morphine-induced scratching and antinociception. Anesthesiology. 2000;92(3):795–805. doi: 10.1097/00000542-200003000-00023.Patel T, Yosipovitch G. Therapy of pruritus. Exp Opin Pharmacother. 2010;11(10):1673–1682. doi: 10.1517/14656566.2010.484420.Patel T, Yosipovitch G. Therapy of pruritus. Exp Opin Pharmacother. 2010;11(10):1673–1682. doi: 10.1517/14656566.2010.484420.Elmariah SB, Lerner EA. Topical Therapies for Pruritus. Semin Cutan Med Surg. 2011;30(2):118–126. doi: 10.1016/j.sder.2011.04.008.Elmariah SB, Lerner EA. Topical Therapies for Pruritus. Semin Cutan Med Surg. 2011;30(2):118–126. doi: 10.1016/j.sder.2011.04.008.Dillon SR, Sprecher C, Bilsborough J, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004;5(7):752–760. doi: 10.1038/ni1084.Dillon SR, Sprecher C, Bilsborough J, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004;5(7):752–760. doi: 10.1038/ni1084.Bilsborough J, Leung DY, Маuer М, et al. IL-31 is associated with. Cutaneous lymphocyte antigen-positive skin homing Т cells in patients with atopic dermatitis. J Allergy Clin Immunol. 2006; 117(2):418–425. doi: 10.1016/j.jaci.2005.10.046.Bilsborough J, Leung DY, Маuer М, et al. IL-31 is associated with. Cutaneous lymphocyte antigen-positive skin homing Т cells in patients with atopic dermatitis. J Allergy Clin Immunol. 2006; 117(2):418–425. doi: 10.1016/j.jaci.2005.10.046.Jоhnаnssоn О, Liang Y, Marcusson JА, Reimert СМ. Eosinophil cationic protein- and eosinophil-derived nеurоtохin/ еosinophil protein Х-immunoreactive eosinophils in prurigo nodularis. Arch Dermatol Res. 2000;292(8):371–378. doi: 10.1007/s004030000142.Jоhnаnssоn О, Liang Y, Marcusson JА, Reimert СМ. Eosinophil cationic protein- and eosinophil-derived nеurоtохin/ еosinophil protein Х-immunoreactive eosinophils in prurigo nodularis. Arch Dermatol Res. 2000;292(8):371–378. doi: 10.1007/s004030000142.Kapp А. The role of еosinophil in раthоgеnеsis of atopic dermatitis — еosinophil granule proteins as markers of disease activity. Allergy. 1993;48(1):1–5. doi: 10.1111/j.1398-9995.1993.tb02167.x.Kapp А. The role of еosinophil in раthоgеnеsis of atopic dermatitis — еosinophil granule proteins as markers of disease activity. Allergy. 1993;48(1):1–5. doi: 10.1111/j.1398-9995.1993.tb02167.x.Raap U, Goltz С, Deneka N, et al. Brain-derived neurotrophic factor is increased in atopic dermatitis and modulates eosiniophil functions compared with that seen in non-atopic subjects. J Allergy Clin Immunol. 2005;115(6):1268–1275. doi: 10.1016/j.jaci.2005.02.007.Raap U, Goltz С, Deneka N, et al. Brain-derived neurotrophic factor is increased in atopic dermatitis and modulates eosiniophil functions compared with that seen in non-atopic subjects. J Allergy Clin Immunol. 2005;115(6):1268–1275. doi: 10.1016/j.jaci.2005.02.007.Raap U, Werfel Т, Goltz С, et аl. Circulating levels of brain-derived neurotrophic factor correlates with disease severity in the intrinsic type of atopic dermatitis. Allergy. 2006;61(12):1416–1418. doi: 10.1111/j.1398-9995.2006.01210.x.Raap U, Werfel Т, Goltz С, et аl. Circulating levels of brain-derived neurotrophic factor correlates with disease severity in the intrinsic type of atopic dermatitis. Allergy. 2006;61(12):1416–1418. doi: 10.1111/j.1398-9995.2006.01210.x.Raap U, Kapp А. Neuroimmunological findings in allergic skin diseases. Сurr Opin Allergy Clin Immunol. 2005;5(5):419–424. doi: 10.1097/01.all.0000183111.78558.4d.Raap U, Kapp А. Neuroimmunological findings in allergic skin diseases. Сurr Opin Allergy Clin Immunol. 2005;5(5):419–424. doi: 10.1097/01.all.0000183111.78558.4d.Remrod С, Lonne-Rahm S, Nordlind К. Study of substance Р аnd its receptor neurokinin-l in psoriasis and their relation to chronic stress and pruritus. Arch Dermatol Res. 2007;299(2):85–91. doi: 10.1007/s00403-007-0745-x.Remrod С, Lonne-Rahm S, Nordlind К. Study of substance Р аnd its receptor neurokinin-l in psoriasis and their relation to chronic stress and pruritus. Arch Dermatol Res. 2007;299(2):85–91. doi: 10.1007/s00403-007-0745-x.Huang YJ, Marsland BJ, Bunyavanich S, et al. The microbiome in allergic disease: Current understanding and future opportunities — 2017 PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology. J Allergy Clin Immunol. 2017;139(4): 1099–1110. doi: 10.1016/j.jaci.2017.02.007.Huang YJ, Marsland BJ, Bunyavanich S, et al. The microbiome in allergic disease: Current understanding and future opportunities — 2017 PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology. J Allergy Clin Immunol. 2017;139(4): 1099–1110. doi: 10.1016/j.jaci.2017.02.007.Engebretsen KA, Linneberg A, Thuesen BH, et al. Xerosis is associated with asthma in men independent of atopic dermatitis and filaggrin gene mutations. J Eur Acad Dermatol Venereol. 2015; 29(9):1807–1815. doi: 10.1111/jdv.13051.Engebretsen KA, Linneberg A, Thuesen BH, et al. Xerosis is associated with asthma in men independent of atopic dermatitis and filaggrin gene mutations. J Eur Acad Dermatol Venereol. 2015; 29(9):1807–1815. doi: 10.1111/jdv.13051.Pellerin L, Henry J, Hsu CY, et al. Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin. J Allergy Clin Immunol. 2013;131(4):1094–1102. doi: 10.1016/j.jaci.2012.12.1566.Pellerin L, Henry J, Hsu CY, et al. Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin. J Allergy Clin Immunol. 2013;131(4):1094–1102. doi: 10.1016/j.jaci.2012.12.1566.Howell MD, Kim BE, Boguniewicz M, Leung DYM. Modulation of filaggrin by Th2 cytokines in the skin of Atopic Dermatitis (AD). J Allergy Clin Immunol. 2007;119(1):S283.Howell MD, Kim BE, Boguniewicz M, Leung DYM. Modulation of filaggrin by Th2 cytokines in the skin of Atopic Dermatitis (AD). J Allergy Clin Immunol. 2007;119(1):S283.N orman RA. Xerosis and pruritus in the elderly: recognition and management. Dermatol Ther. 2003;16(3):254–259. doi: 10.1046/j.1529-8019.2003.01635.x.N orman RA. Xerosis and pruritus in the elderly: recognition and management. Dermatol Ther. 2003;16(3):254–259. doi: 10.1046/j.1529-8019.2003.01635.x.Fjellner В, Arnetz ВВ. Psychological predictors of pruritus during mental stress. Acta Dermatol Venereol. 1985;65(6):504–508.Fjellner В, Arnetz ВВ. Psychological predictors of pruritus during mental stress. Acta Dermatol Venereol. 1985;65(6):504–508.Wahlgren CF. Pathophysiology of itching in urticaria and atopic dermatitis. Allergy. 1992;47(2 Pt 1):65–75. doi: 10.1111/j.1398-9995.1992.tb05091.x.Wahlgren CF. Pathophysiology of itching in urticaria and atopic dermatitis. Allergy. 1992;47(2 Pt 1):65–75. doi: 10.1111/j.1398-9995.1992.tb05091.x.Намазова-Баранова Л.С., Баранов А.А., Кубанова А.А. и др. Атопический дерматит у детей: современные клинические рекомендации по диагностике и терапии // Вопросы современной педиатрии. — 2016. — Т. 15. — № 3. — С. 279–293. doi: 10.15690/vsp.v15i3.1566.Namazova-Baranova LS, Baranov AA, Kubanova AA, et al. Atopic Dermatitis in Children: Current Clinical Guidelines for Diagnosis and Therapy. Voprosy sovremennoi pediatrii — Current Pediatrics. 2016;15(3):279–294. (In Russ). doi: 10.15690/vsp.v15i3.1566.Yvette A. Tivoli, DO, Rubenstein RM. Pruritus. J Clin Aesthet Dermatol. 2009;2(7):30–36.Yvette A. Tivoli, DO, Rubenstein RM. Pruritus. J Clin Aesthet Dermatol. 2009;2(7):30–36.Мурашкин Н.Н., Материкин А.И., Амбарчян Э.Т. и др. Дерма то логические аспекты зуда // Педиатрия (Прил. к журн. Consilium Medicum). — 2018. — № 1. — С. 121–125. doi: 10.26442/2413-8460_2018.1.121-125.Murashkin NN., Materikin AI, Ambarchyan ET, et al. Dermatologic aspects of pruritus. Pediatrics (Suppl. Consilium Medicum). 2018;1:121–125. (In Russ). doi: 10.26442/2413-8460_2018.1.121-125.Reunala T, Salmi TT, Hervonen K, et al. Dermatitis Herpetiformis: A Common Extraintestinal Manifestation of Coeliac Disease. Nutrients. 2018;10(5):602. doi: 10.3390/nu10050602.Reunala T, Salmi TT, Hervonen K, et al. Dermatitis Herpetiformis: A Common Extraintestinal Manifestation of Coeliac Disease. Nutrients. 2018;10(5):602. doi: 10.3390/nu10050602.Kulczycka-Siennicka L, Cynkier A, Waszczykowska E, et al. The Role of Intereukin-31 in Pathogenesis of Itch and Its Intensity in a Course of Bullous Pemphigoid and Dermatitis Herpetiformis. Biomed Res Int. 2017;2017:5965492. doi: 10.1155/2017/5965492.Kulczycka-Siennicka L, Cynkier A, Waszczykowska E, et al. The Role of Intereukin-31 in Pathogenesis of Itch and Its Intensity in a Course of Bullous Pemphigoid and Dermatitis Herpetiformis. Biomed Res Int. 2017;2017:5965492. doi: 10.1155/2017/5965492.Hong J, Buddenkotte J, Berger TG, Steinhoff M. Management of Itch in Atopic Dermatitis. Semin Cutan Med Surg. 2011;30(2): 71–86. doi: 10.1016/j.sder.2011.05.002.Hong J, Buddenkotte J, Berger TG, Steinhoff M. Management of Itch in Atopic Dermatitis. Semin Cutan Med Surg. 2011;30(2): 71–86. doi: 10.1016/j.sder.2011.05.002.Bock SA. The natural history of food sensitivity. J Allergy Clin Immunol. 1982;69(2):173–117. doi: 10.1016/0091-6749(82)90096-3.Bock SA. The natural history of food sensitivity. J Allergy Clin Immunol. 1982;69(2):173–117. doi: 10.1016/0091-6749(82)90096-3.Leung DY, Harbeck R, Bina P, et al. Presence of IgE antibo dies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. J Clin Invest. 1993; 92(3):1374–1380. doi: 10.1172/JCI116711.Leung DY, Harbeck R, Bina P, et al. Presence of IgE antibo dies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. J Clin Invest. 1993; 92(3):1374–1380. doi: 10.1172/JCI116711.Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: Outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol. 2008;121(6):1337–1343. doi: 10.1016/j.jaci.2008.01.022.Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: Outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol. 2008;121(6):1337–1343. doi: 10.1016/j.jaci.2008.01.022.Vilaplana J, Coll J, Trullas C, et al: Clinical and non-invasive evaluation of 12% ammonium lactate emulsion for the treatment of dry skin in atopic and non-atopic subjects. Acta Derm Venereol. 1992;72(1):28–33.Vilaplana J, Coll J, Trullas C, et al: Clinical and non-invasive evaluation of 12% ammonium lactate emulsion for the treatment of dry skin in atopic and non-atopic subjects. Acta Derm Venereol. 1992;72(1):28–33.Patel T, Ishiuji Y, Yosipovitch G. Menthol: a refreshing look at this ancient compound. J Am Acad Dermatol. 2007;57(5):873–878. doi: 10.1016/j.jaad.2007.04.008.Patel T, Ishiuji Y, Yosipovitch G. Menthol: a refreshing look at this ancient compound. J Am Acad Dermatol. 2007;57(5):873–878. doi: 10.1016/j.jaad.2007.04.008.Summey BT, Jr, Yosipovich G. Pharmacologic advances in the systemic treatment of itch. Dermatol Ther. 2005;18(4):328–332. doi: 10.1111/j.1529-8019.2005.00035.x.Summey BT, Jr, Yosipovich G. Pharmacologic advances in the systemic treatment of itch. Dermatol Ther. 2005;18(4):328–332. doi: 10.1111/j.1529-8019.2005.00035.x.Buddenkotte J, Steinhoff M. Pathophysiology and therapy of pruritus in allergic and atopic diseases. Allergy. 2010;65(7):805–821. doi: 10.1111/j.1398-9995.2010.01995.x.Buddenkotte J, Steinhoff M. Pathophysiology and therapy of pruritus in allergic and atopic diseases. Allergy. 2010;65(7):805–821. doi: 10.1111/j.1398-9995.2010.01995.x.Wahlgren CF, Scheynius A, Hagermark O. Antipruritic effect of oral cyclosporin A in atopic dermatitis. Acta Derm Venereol. 1990; 70(4):323–329.Wahlgren CF, Scheynius A, Hagermark O. Antipruritic effect of oral cyclosporin A in atopic dermatitis. Acta Derm Venereol. 1990; 70(4):323–329.Sowden JM, Berth-Jones J, Ross JS, et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet. 1991;338(8760):137–140. doi: 10.1016/0140-6736(91)90134-b.Sowden JM, Berth-Jones J, Ross JS, et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet. 1991;338(8760):137–140. doi: 10.1016/0140-6736(91)90134-b.Rivard J, Lim HW. Ultraviolet phototherapy for pruritus. Dermatol Ther. 2005;18(4):344–354. doi: 10.1111/j.1529-8019.2005.00032.x.Rivard J, Lim HW. Ultraviolet phototherapy for pruritus. Dermatol Ther. 2005;18(4):344–354. doi: 10.1111/j.1529-8019.2005.00032.x.Gupta MA, Gupta AK, Schork NJ, et al. Depression modulates pruritus perception: A study of pruritus in psoriasis, atopic dermatitis, and chronic idiopathic urticaria. Psychosom Med. 1994; 56(1):36–40. doi: 10.1097/00006842-199401000-00005.Gupta MA, Gupta AK, Schork NJ, et al. Depression modulates pruritus perception: A study of pruritus in psoriasis, atopic dermatitis, and chronic idiopathic urticaria. Psychosom Med. 1994; 56(1):36–40. doi: 10.1097/00006842-199401000-00005.Wang F-P, Tang X-J, Wei C-Q, et al. Dupilumab treatment in mode rate-to-severe atopic dermatitis: a systematic review and meta-analysis. J Dermatol Sci. 2018;90(2):190–198. doi: 10.1016/j.jdermsci.2018.01.016.Wang F-P, Tang X-J, Wei C-Q, et al. Dupilumab treatment in mode rate-to-severe atopic dermatitis: a systematic review and meta-analysis. J Dermatol Sci. 2018;90(2):190–198. doi: 10.1016/j.jdermsci.2018.01.016.Kabashima K, Furue M, Hanifin JM, et al. Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study. J Allergy Clin Immunol. 2018; 142:1121–1130.e7. doi: 10.1016/j.jaci.2018.03.018.Kabashima K, Furue M, Hanifin JM, et al. Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study. J Allergy Clin Immunol. 2018; 142:1121–1130.e7. doi: 10.1016/j.jaci.2018.03.018.Yosipovitch G, Rosen JD, Hashimoto Ti. Itch: From mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol. 2018; 142(5):1375–1390. doi: 10.1016/j.jaci.2018.09.005.Yosipovitch G, Rosen JD, Hashimoto Ti. Itch: From mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol. 2018; 142(5):1375–1390. doi: 10.1016/j.jaci.2018.09.005.Fukuyama T, Ganchingco JR, Mishra SK, et al. Janus kinase inhibitors display broad anti-itch properties: a possible link through the TRPV1 receptor. J Allergy Clin Immunol. 2017;140(1):306–309. e3. doi: 10.1016/j.jaci.2016.12.960.Fukuyama T, Ganchingco JR, Mishra SK, et al. Janus kinase inhibitors display broad anti-itch properties: a possible link through the TRPV1 receptor. J Allergy Clin Immunol. 2017;140(1):306–309. e3. doi: 10.1016/j.jaci.2016.12.960.Heil PM, Maurer D, Klein B, et al. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course — a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges. 2010;8(12):990–998. doi: 10.1111/j.1610-0387.2010.07497.x.Heil PM, Maurer D, Klein B, et al. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course — a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges. 2010;8(12):990–998. doi: 10.1111/j.1610-0387.2010.07497.x.Schommer A, Matthies C, Petersen I, Augustin M. Effektivitat einer Polidocanol–Harnstoff–Kombination bei trockener, juckender Haut. Ergebnisse einer methodisch gepruften Anwendungsbeobachtung. Aktuelle Dermatologie. 2007;33(01/02):33–38. doi: 10.1055/s-2006-945179.Schommer A, Matthies C, Petersen I, Augustin M. Effektivitat einer Polidocanol–Harnstoff–Kombination bei trockener, juckender Haut. Ergebnisse einer methodisch gepruften Anwendungsbeobachtung. Aktuelle Dermatologie. 2007;33(01/02):33–38. doi: 10.1055/s-2006-945179.Hauss H, Proppe A, Matthies C. Vergleichende Untersuchungen zur Behandlung von trockener, juckender Haut mit einer Zubereitung aus Harnstoff und Polidocanol sowie mit einer Linolsaure-haltigen Fettcreme. Dermatosen in Beruf und Umwelt = Occupation and environment. 1993;41(5):184–188.Hauss H, Proppe A, Matthies C. Vergleichende Untersuchungen zur Behandlung von trockener, juckender Haut mit einer Zubereitung aus Harnstoff und Polidocanol sowie mit einer Linolsaure-haltigen Fettcreme. Dermatosen in Beruf und Umwelt = Occupation and environment. 1993;41(5):184–188.Spoo J, Schliemann-Willers S, Elsner P. Evaluation of the antihistaminergic efficfcy of STIMU-TEX® AS on iontophoretically induced histamine irritftion by laser Doppler flowmetry. Test report. Available online: https://atopicbaby.ru/clinical_trials/stimu-tex-as-in-vivorelief-of-histamine-related-symptoms. Accessed on June 20, 2020.Spoo J, Schliemann-Willers S, Elsner P. Evaluation of the antihistaminergic efficfcy of STIMU-TEX® AS on iontophoretically induced histamine irritftion by laser Doppler flowmetry. Test report. Available online: https://atopicbaby.ru/clinical_trials/stimu-tex-as-in-vivorelief-of-histamine-related-symptoms. Accessed on June 20, 2020.Мигачева Н.Б., Орлов Е.В., Чаплыгина С.И. и др. Инновационные средства ухода за кожей детей с атопическим дерматитом // РМЖ. — 2017. — № 19. — С. 1391–1395.Migacheva NB, Orlov EV, Chaplygina SI, et al. Innovative skin care products for children with atopic dermatitis. RMJ. 2017;(19): 1391–1395. (In Russ).Ларькова И.А., Ревякина В.А., Кравцова П.О., Кувшинова Е.Д. Современные средства ухода за кожей в базисной терапии атопического дерматита у детей // Педиатрия (Прил. к журн. Consilium Medicum). — 2017. — № 1. — 86–88.Larkova IA, Reviakina VA, Kravtsova PO, Kuvshinova ED. Modern means of skin care in the basic therapy of atopic dermatitis in children. Pediatrics (Suppl. Consilium Medicum). 2017;1:86–88. (In Russ).Елисютина О.Г., Литовкина А.О., Феденко Е.С. Опыт использования современных средств по уходу за кожей серии Атопик® у детей с атопическим дерматитом // Российский аллергологический журнал. — 2017. — Т. 14. — №. 2. — С. 76–81.Elisyutina O.G., Litovkina A.O., Fedenko E.S. Experience of modern skin care series Atopic® using in atopic dermatitis children. Russian Journal of Allergy. 2017;14(2):76–81. (In Russ).Нурпеисов Т.Т., Беркинбаев С.Ф., Газалиева М.А., Хан В.В. Применение комплекса топических средств для лечения атопического дерматита у детей // Вопросы практической педиатрии. — 2017. — Т. 12. — № 5. — С. 73–77. doi: 10.20953/1817-7646-2017-5-73-77.Nurpeisov TT, Berkinbaev SF, Gazalieva MA, Khan VV. Use of a complex of topic preparations for treatment of atopic dermatitis in children. Voprosy Practicheskoi Pediatrii. 2017;12(5):73–77. (In Russ). doi: 10.20953/1817-7646-2017-5-73-77.

The authors declare that there are no conflicts of interest present.